MINNEAPOLIS, MN—Treatment with acoramidis (Attruby; BridgeBio Pharma) compared with placebo appears to reduce cumulative cardiovascular events by almost half among patients who have transthyretin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback